We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×

Home > News > Psychedelics

Novel Psychedelic Molecule Shows Promise in Pre-Clinical Cocaine Addiction Treatment Trial

Published: Jun 09, 2022   

Complete the form below and we will email you a PDF version of "Novel Psychedelic Molecule Shows Promise in Pre-Clinical Cocaine Addiction Treatment Trial "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Analytical Cannabis?

Analytical Cannabis Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Novel Psychedelic Molecule Shows Promise in Pre-Clinical Cocaine Addiction Treatment Trial

Clearmind Medicine has announced positive pre-clinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule.

"This exciting research on MEAI could go a long way in helping those who need it," said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer. “While effective treatments for opioid addictions have been available, this could be the first dedicated treatment for cocaine addiction, which is a global crisis.”

The pre-clinical trial, led by Professor Gal Yadid and his team, from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel), was designed to evaluate possible reward-like effects of MEAI, on male Sprague-Dawley rats based on the Conditioned Place Preference (CPP*) model.

Rats previously conditioned with cocaine received either cocaine (at 15mg/kg) or MEAI at doses of 2.5, 5, 10 and 20 mg/kg. Rats treated with MEAI spent less time in the compartment associated with cocaine. Results suggest a potential role for MEAI in abolishing cocaine-induced conditioned place preference and eliminating heightened craving, and that the compound was not itself addictive. The 5 mg/kg dose was found the most effective dose and selected for further study.

The results followed Clearmind's recent news regarding filing a provisional patent application related to cocaine addiction.

"Once again, MEAI has shown the potential to become a game changer in the field of addiction treatments" Zuloff- Shani added. "We intend to further explore the potential of MEAI as an anti-cocaine addiction treatment."


This article has been republished from materials provided by Clearmind Medicine. Note: material may have been edited for length and content. For further information, please contact the cited source.

 

Like what you just read? You can find similar content on the topic tags shown below.

Science & Health Psychedelics

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

 
Advertisement